SCHEMBL1110267

SCHEMBL1110267

O=S(=O)(Nc1cccc2c(O)cccc12)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HKDC1 Q2TB90 2/20 0.63
▸ ACLY P53396 7/20 0.56
▸ DNMT1 P26358 1/20 0.53
▸ DNMT3A Q9Y6K1 1/20 0.53
▸ EP300 Q09472 1/20 0.52
▸ KAT2B Q92831 1/20 0.52
▸ KAT8 Q9H7Z6 1/20 0.52
▸ GAA P10253 2/20 0.49
▸ PSD A5PKW4 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ MITF O75030 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ THRB P10828 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ CASP1 P29466 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6275069 0.84 ACLY (0.69) ACLYGAAMEN1KMT2AALDH1A1
SCHEMBL1110445 0.82 KEAP1 (0.49) HKDC1ACLY
SCHEMBL1319104 0.82 RECQL (0.69) ACLYMEN1KMT2AALDH1A1LMNA
SCHEMBL1110317 0.82 ACLY (0.63) ACLYMEN1KMT2ALMNA
SCHEMBL10409886 0.81 RECQL (0.68) HKDC1EP300KAT2BKAT8GAA
SCHEMBL11334681 0.81 HKDC1 (0.55) HKDC1DNMT1DNMT3AEP300KAT2B
SCHEMBL1110283 0.81 ACLY (0.51) HKDC1ACLYALDH1A1HPGD
SCHEMBL29561494 0.80 ACLY (0.60) HKDC1ACLYGAAMEN1KMT2A
SCHEMBL10421081 0.79 HKDC1 (0.52) HKDC1DNMT1DNMT3AEP300KAT2B
SCHEMBL9460434 0.79 HKDC1 (0.52) HKDC1DNMT1DNMT3AEP300KAT2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 — — US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 — — US disclosed
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 — — US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 — — EP disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 — — WO disclosed
WO-2009127723-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 HKDC1 624/4885ACLY 1173/4885DNMT1 3617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback